An AI-designed drug appeared to make patients biologically 'younger' across six different ageing clocks in a small trial of idiopathic pulmonary fibrosis, according to research published in Nature Biotechnology on 7 September 2026.
Rentosertib, an investigational TNIK inhibitor developed by Insilico Medicine, showed its clearest signal after four weeks at 30 mg twice daily in a secondary analysis of a Phase 2a study that was primarily designed to assess safety and tolerability.
